Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04822077
Other study ID # PROTHYM 2.2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 18, 2018
Est. completion date April 1, 2029

Study information

Verified date March 2021
Source Swedish Lung Cancer Study Group
Contact Jan Nyman, Ass.prof.
Phone +46313421000
Email jan.nyman@oncology.gu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease. Patients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients. Primary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern


Description:

All doses are recorded in Gy(RBE). After having checked all eligibility criteria patients will receive: - Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE). - Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE) - Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE) - Patients not willing to participate in study will receive photon therapy according to local practice (≥45 Gy) Induction or adjuvant chemotherapy may be used according to local practice. Concomitant chemotherapy is not allowed.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 1, 2029
Est. primary completion date April 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histological or cytological diagnosis of thymoma or thymic carcinoma. - With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient/ patient refusing surgery: stage I - IVa, any histology - PS WHO 0 - 2. - FEV1 > 1L or >40 % of predicted and CO diffusion capacity > 40% of predicted (postoperative measures) - Age >18 years, no upper age limit. - Written informed consent from patients. Exclusion Criteria: - Masaoka-Koga stage IVb (distant metastases). - Pregnancy. - Serious concomitant systemic disorder incompatible with the study. - Tumour motion > 0.5 cm on two repeated 4DCT

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Proton radiation
Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE). Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE) Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)

Locations

Country Name City State
Sweden Department of Oncology, Sahlgrenska University Hospital Gothenburg Västra Götaland
Sweden Department of Oncology, Karolinska University Hospital Stockholm Stockholm County
Sweden Department of Oncology, Norrlands Universitetssjukhus Umeå Norrland

Sponsors (1)

Lead Sponsor Collaborator
Ass. Prof. Jan Nyman

Country where clinical trial is conducted

Sweden, 

References & Publications (4)

Björk-Eriksson T, Bjelkengren G, Glimelius B. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma. Acta Oncol. 2005;44(8):913-7. Review. — View Citation

Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):809-18. d — View Citation

Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S336-43. doi: 10.1097/JTO.0b013e3181f20ea2. Review. — View Citation

Vogel J, Berman AT, Lin L, Pechet TT, Levin WP, Gabriel P, Khella SL, Singhal S, Kucharczuk JK, Simone CB 2nd. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and tox — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiotoxicity and pulmonary toxicity of therapy Proportion of patients with cardiac and pulmonary toxicity measured by CTCAE 4.0 > Grade 2 At 60 months from treatment
Primary Local tumor control Freedom from tumor progression (CR,PR or SD) mesured by CT-scan At 60 months from treatment
Secondary Quality of life questionnaire EORTC QLQ 30 (European Organisation for Research and Treatment of Cancer) Scale from 1-100 for 30 items, higher score indicates a better situation. At 60 months from treatment
Secondary Quality of life questionnaire LC13 (Lung cancer specific module of EORTC) Scale from 1-100 for 13 items and higher score indicates worse symptoms. At 60 months from treatment
Secondary Survival Overall survival From treatment and for 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05271162 - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines Phase 3
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Recruiting NCT04092309 - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation N/A
Recruiting NCT04790266 - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT05040867 - Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients N/A
Recruiting NCT05851053 - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation NCT04877899 - Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Recruiting NCT05096338 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting NCT05078190 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Recruiting NCT04632407 - Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study? N/A
Completed NCT00543062 - Staccato Prochlorperazine Thorough QT/QTc Phase 1
Recruiting NCT05159479 - Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Not yet recruiting NCT06005259 - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) Phase 4
Recruiting NCT05406635 - Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer N/A
Recruiting NCT04047901 - Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment N/A
Terminated NCT03038997 - Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Completed NCT01246778 - Sunitinib and Atrial Trabeculae Contractility N/A